Beijing Winsunny Pharmaceutical CO.LTD (601089) - Total Assets
Based on the latest financial reports, Beijing Winsunny Pharmaceutical CO.LTD (601089) holds total assets worth CN¥4.69 Billion CNY (≈ $686.40 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Winsunny Pharmaceutical CO.LTD - Total Assets Trend (2020–2024)
This chart illustrates how Beijing Winsunny Pharmaceutical CO.LTD's total assets have evolved over time, based on quarterly financial data. Also see 601089 stock market capitalisation for the company's overall valuation and market capitalisation.
Beijing Winsunny Pharmaceutical CO.LTD - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Winsunny Pharmaceutical CO.LTD's total assets of CN¥4.69 Billion consist of 66.5% current assets and 33.5% non-current assets. Review 601089 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.5% |
| Accounts Receivable | CN¥354.66 Million | 7.4% |
| Inventory | CN¥347.56 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥139.21 Million | 2.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Beijing Winsunny Pharmaceutical CO.LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Beijing Winsunny Pharmaceutical CO.LTD (601089) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Winsunny Pharmaceutical CO.LTD's current assets represent 66.5% of total assets in 2024, an increase from 62.6% in 2020.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, up from 15.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 7.4% of total assets.
Beijing Winsunny Pharmaceutical CO.LTD Competitors by Total Assets
Key competitors of Beijing Winsunny Pharmaceutical CO.LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs179.65 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Beijing Winsunny Pharmaceutical CO.LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.73 | 3.13 | 3.38 |
| Quick Ratio | 2.39 | 2.79 | 3.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.82 Billion | CN¥2.10 Billion | CN¥2.40 Billion |
Beijing Winsunny Pharmaceutical CO.LTD - Advanced Valuation Insights
This section examines the relationship between Beijing Winsunny Pharmaceutical CO.LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.30 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | CN¥4.82 Billion |
| Market Capitalization | $1.11 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Winsunny Pharmaceutical CO.LTD's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Winsunny Pharmaceutical CO.LTD's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
The table below shows the annual total assets of Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.82 Billion ≈ $704.82 Million |
+5.91% |
| 2023-12-31 | CN¥4.55 Billion ≈ $665.48 Million |
+5.22% |
| 2022-12-31 | CN¥4.32 Billion ≈ $632.44 Million |
+100.73% |
| 2021-12-31 | CN¥2.15 Billion ≈ $315.08 Million |
+25.43% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.21 Million |
-- |
About Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical preparations and medical devices China and internationally. The company provides chemical drugs and traditional chinese medicines. Its products used in cardiovascular kind, chronic kidney disease, skin disease, digestive system, diabetes, neuropsychiatric system kind, mental nervous system… Read more